Goldman Sachs Group Inc. Has $7.85 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Goldman Sachs Group Inc. reduced its stake in Amneal Pharmaceuticals by 3.8%, owning 937,189 shares valued at approximately $7.85 million as of the latest SEC filing.
• Several institutional investors increased their positions in Amneal, with Acadian Asset Management LLC raising its holdings by 51.3%, now owning about $21.76 million worth of shares.
• Goldman Sachs initiated coverage on Amneal Pharmaceuticals with a "buy" rating and a price target of $12.00, alongside a consensus price target of $11.60 from other analysts.

Goldman Sachs Group Inc. reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 937,189 shares of the company's stock after selling 36,556 shares during the period. Goldman Sachs Group Inc. owned approximately 0.30% of Amneal Pharmaceuticals worth $7,854,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Amneal Pharmaceuticals by 2.4% in the first quarter. Rhumbline Advisers now owns 237,913 shares of the company's stock valued at $1,994,000 after purchasing an additional 5,649 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 51.3% in the first quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company's stock valued at $21,759,000 after purchasing an additional 880,471 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Amneal Pharmaceuticals by 5.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock valued at $2,807,000 after purchasing an additional 16,536 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Amneal Pharmaceuticals by 165.2% in the first quarter. Woodline Partners LP now owns 1,504,095 shares of the company's stock valued at $12,604,000 after purchasing an additional 937,035 shares during the last quarter. Finally, Caxton Associates LLP acquired a new stake in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $339,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group initiated coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $11.60.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the transaction, the executive vice president directly owned 152,743 shares of the company's stock, valued at $1,475,497.38. The trade was a 42.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the transaction, the executive vice president directly owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 609,206 shares of company stock valued at $5,700,625. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Trading Down 0.9%

Shares of AMRX opened at $10.00 on Friday. The company has a market cap of $3.14 billion, a price-to-earnings ratio of 1,001.00 and a beta of 1.19. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.68 and a 1-year high of $10.34. The company's fifty day simple moving average is $8.83 and its 200 day simple moving average is $8.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.